molecules of the month

BAY 1895344

selective oral ATR kinase inhibitor

in Ph. I for adv. solid tumors and lymphomas

from HTS and modeling on PI3Kg structure

J. Med. Chem., Jun. 5, 2020

Bayer AG, Berlin, DE

Structure of ATR inhibitor BAY 1895344
1 min read

BAY 1895344 is a potent and highly selective inhibitor of the ATR kinase, which is involved in the DNA damage response. Further disruption of the DNA damage response via ATR inhibition is expected to induce synthetic lethality in cancers with already impaired DNA damage repair mechanisms. The Bayer team was able to overcome poor solubility in an initial lead to identify a highly orally bioavailable molecule. The acceptable solubility of 344 despite multiple aromatic rings is believed to be due to the out-of-plane bias of the methylpyrazole motif relative to the naphthyridine ring.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: